■比较使用RurioctocogAlfaPegol(FVIII-PEG)与抗血友病因子(重组)治疗的非抑制剂性血友病A患者的医疗费用,FC融合蛋白(rFVIIIFc)。
来自Merative™MarketScan®商业(商业)和医疗补助(医疗补助)数据库的行政索赔数据用于这些分析。确定了从2016年1月1日至2021年3月31日用FVIII-PEG或rFVIIIFc治疗的非抑制剂血友病A的男性(最早的治疗=指数)。患者需要在索引日期之前和之后连续六个月进行数据库登记。随访时间长短可变,直到退役或研究结束。每个患者每月报告全因和血友病相关的医疗保健费用[PPPM],并比较治疗组之间随访期间的平均每周剂量。使用广义线性回归来估计两个治疗组中总费用和每周剂量的多变量调整差异。
■共有131名FVIII-PEG(66名商业;65名医疗补助)和204名rFVIIIFc(111名商业;93名医疗补助)患者符合条件。商业FVIII-PEG和rFVIIIFc的平均年龄为20.5和24.4,医疗补助中FVIII-PEG和rFVIIIFc的平均年龄为14.9和17.5。商业保险患者的PPPM平均值(标准差[SD])FVIII-PEG的总医疗费用为35,868美元[21,717美元],rFVIIIFc的40,424美元[25,882美元]。FVIII-PEG的医疗补助费用为27,495美元[23,243美元],rFVIIIFc的医疗补助费用为30,237美元[28,430美元]。调整基线特性后,rFVIIIFc(vsFVIII-PEG)的成本在商业上增加了5,215美元,在医疗补助上增加了3,895美元,但差异无统计学意义(p>0.05)。对于血友病特定的医疗保健成本也观察到了类似的发现。调整后的平均每周剂量为6,047vs4,892IU,商业FVIII-PEG与rFVIIIFc的p=0.21,5,549与7,228IU,医疗补助中FVIII-PEG与rFVIIIFc的p=0.07。
■对于用FVIII-PEG和rFVIIIFc治疗的非抑制剂血友病A患者,医疗保健成本和治疗剂量相似(p>0.05)。
UNASSIGNED: To compare healthcare costs in patients with non-inhibitor hemophilia A treated with Rurioctocog Alfa Pegol (FVIII-PEG) versus Antihemophilic Factor (Recombinant), FC Fusion Protein (rFVIIIFc).
UNASSIGNED: Administrative claims data from the Merative MarketScan Commercial (Commerical) and Medicaid (Medicaid) databases were used for these analyses. Males with non-inhibitor hemophilia A treated with FVIII-PEG or rFVIIIFc from 1 January 2016 to 31 March 2021 were identified (earliest treatment = index). Patients were required to have continuous database enrollment for six months before and after the index date. Follow-up was variable in length until disenrollment or study end. All-cause and hemophilia-related healthcare costs were reported per-patient per month [PPPM] and the average weekly dose during follow-up was compared between treatment groups. Generalized linear regressions were used to estimate multivariable-adjusted differences in total costs and weekly dosage in the two treatment groups.
UNASSIGNED: A total of 131 FVIII-PEG (66 Commercial; 65 Medicaid) and 204 rFVIIIFc (111 Commercial; 93 Medicaid) patients were eligible. Mean age was 20.5 and 24.4 for FVIII-PEG and rFVIIIFc in Commercial and 14.9 and 17.5 for FVIII-PEG and rFVIIIFc in Medicaid. PPPM mean (standard deviations [SD]) total healthcare costs in Commercially insured patients were $35,868 [$21,717] for FVIII-PEG vs $40,424 [$25,882] for rFVIIIFc. Costs in Medicaid were $27,495 [$23,243] for FVIII-PEG vs $30,237 [$28,430] for rFVIIIFc. After adjusting for baseline characteristics, the costs for rFVIIIFc (vs FVIII-PEG) were higher by $5,215 in Commercial and $3,895 in Medicaid, but the differences were not statistically significant (p > 0.05). Similar findings were observed for hemophilia-specific healthcare costs. The adjusted mean weekly dose was 6,047 vs 4,892 IU, p = 0.21 for FVIII-PEG vs rFVIIIFc in Commercial and 5,549 vs 7,228 IU, p = 0.07 for FVIII-PEG vs rFVIIIFc in Medicaid.
UNASSIGNED: Healthcare costs and treatment dosing were similar (p > 0.05) for non-inhibitor hemophilia A patients treated with FVIII-PEG and rFVIIIFc.